vitro 14 . These results raise the possibility that SGs play an important role in tau-mediated neurodegeneration. Here we show that reducing TIA1 in vivo decreased pSGs, protected against neurodegeneration, improved memory and prolonged the lifespan in PS19 transgenic tau mice. Unexpectedly, this behavioral protection occurred despite the increased accumulation of neurofibrillary tangles (NFTs). Strikingly, we show that levels of TIA1 control the accumulation of tau oligomers and associated RBPs. This work suggests that the pathophysiology of tauopathy is dependent on the interaction of tau with RBPs and adds tauopathies such as AD and FTD to the growing list of diseases linked to the dysfunction of RNA metabolism.
Results
Tia1 haploinsufficiency reduces cytoplasmic translocation of Tia1 and SG formation. We used the PS19 transgenic mouse line, which overexpresses human P301S 1N4R tau under the control of the mouse prion promoter, to investigate whether reduction in endogenous TIA1 also protects against the progression of tauopathy in vivo 16 . We bred PS19 mice with Tia1 −/− mice to generate littermate tauopathy mice that possess either one or two copies of the Tia1 allele, which we will refer to as P301S Tia1 +/− and P301S Tia1 +/+ mice, respectively 17 . Analysis of endogenous TIA1 protein levels in the brain by immunoblot confirmed that TIA1 protein expression was reduced by > 50% in 3-month-old P301S Tia1 +/compared to P301S Tia1 +/+ mice (Fig. 1a,b ). We next investigated whether P301S Tia1 +/mice exhibited reduced cytoplasmic TIA1 granules. Immunohistochemistry (IHC) of hippocampal neurons in P301S Tia1 +/mice revealed > 50% reduction in the number of cytoplasmic TIA1 granules compared to P301S Tia1 +/+ mice ( Supplementary Fig. 1a,b) , as well as a similar reduction in cytoplasmic TIA1 puncta co-localizing with the SG marker PABP (Fig. 1c,d) . The P301S Tia1 +/+ mice also exhibited considerable depletion of nuclear TIA1, consistent with the disease process producing chronic stress (Fig. 1) . In contrast, P301S Tia1 +/mice were protected against loss of nuclear TIA1 (Fig. 1e,f) . IHC for markers of other types of RNA granules demonstrated that TIA1 reduction increased immunofluorescence levels and puncta for the transport granule marker Staufen and the processing-body marker DCP1A ( Fig. 1g-k) . These data show that heterozygous knockout of Tia1 selectively inhibits the formation of cytoplasmic TIA1 granules and loss of nuclear TIA1 in vivo. TIA1 reduction protects against synaptic and neuronal loss in PS19 mice. We proceeded to investigate whether TIA1 reduction also reduces synaptic and neuronal degeneration in vivo. PS19 mice exhibit progressive neuronal loss between 6 and 12 months of age, preceded by presynaptic degeneration 16 . We examined the CA3 region of the hippocampus, because of its high density of axon terminals and neuronal cell bodies and because synaptic and neuronal losses in PS19 mice are well characterized in this region. Compared to non-transgenic littermates, 6-month-old P301S Tia1 +/+ mice exhibited reduced immunofluorescence of synaptophysin, a presynaptic terminal protein, consistent with prior reports ( Fig. 2a,b) 16 . In contrast, synaptophysin immunofluorescence was rescued in P301S Tia1 +/compared to P301S Tia1 +/+ mice ( Fig. 2a,b ), indicating reduced presynaptic degeneration. We also immunostained P301S Tia1 +/+ and P301S Tia1 +/cells for a second axonal structural protein, neurofilament (NFL; Supplementary Fig. 2 ). While P301S Tia1 +/+ mice exhibited decreased immunofluorescence of NFL in 9-month-old CA3, TIA1 haploinsufficiency increased NFL immunofluorescence to a level comparable to that in non-transgenic controls ( Supplementary Fig. 2a -c). Thus, TIA1 reduction appears to protect against presynaptic degeneration up to 9 months of age in P301S Tau mice.
Tau binds and stabilizes microtubules (MTs), which promotes axonal outgrowth and fast axonal transport. We investigated whether TIA1 reduction might protect binding of tau to MTs in these mice. MT-bound (pellet, P) and unbound (supernatant, S) fractions were separated by centrifugation in RAB (reassembly) buffer, as described previously 16 . As expected, tau progressively accumulated in the MT-unbound (S) fraction of P301S Tia1 +/+ mice between 6 and 9 months of age, indicating dissociation of tau from MTs (Fig. 2c ). In contrast, significantly less tau was detected in the MT-unbound (S) fraction of P301S Tia1 +/mice, resulting in a threefold increase in the ratio of MT-bound (P) to unbound (S) tau at 9 months of age ( Fig. 2c,d and Supplementary Fig. 3 ). These data indicate that TIA1 reduction protects the synaptic arbor against taumediated degeneration while providing an associated stabilization of MTs. We quantified total neuron numbers in the hippocampus (CA3) and lateral entorhinal cortex (LEnt) of P301S Tia1 +/+ and P301S Tia1 +/mice. As previously reported, neurons in the hippocampus of P301S TIA +/+ mice were reduced by 6 months of age 16 . The number of Nissl + neurons and NeuN (neuron-specific nuclear protein)positive nuclei were increased in P301S Tia1 +/mice compared to P301S Tia1 +/+ mice in both CA3 and LEnt at 9 months of age ( Fig. 3a-c and Supplementary Fig. 4a ). We also assessed the effect of TIA1 reduction on gross cortical atrophy by measuring the distance between the most superficial part of layer II and the deepest part of layer III (Fig. 3d ) in the LEnt and primary somatosensory cortex of 9-month-old P301S Tia1 +/+ and P301S Tia1 +/mice. P301S Tia1 +/+ mice exhibited 54% and 21% reductions in layer II/III thickness in LEnt and primary somatosensory cortex, respectively, while P301S Tia1 +/mice were not significantly different from non-transgenic mice ( Fig. 3e and Supplementary Fig. 4b ). Taken together, our data suggest that TIA1 reduction protects against tau-mediated neurodegeneration in vivo.
TIA1 reduction alleviates cognitive impairment and extends lifespan in PS19 mice. We next sought to determine whether TIA1 reduction improved the behavioral phenotype of PS19 mice. Previous studies found that PS19 mice exhibit cognitive impairment 18 . In the Y-maze spontaneous alternation task (SAT), 6-month-old P301S Tia1 +/+ mice exhibited reduced spontaneous alternation compared to non-transgenic mice (Fig. 4a ), indicating an impairment in spatial working memory similar to that previously reported in PS19 mice. Notably, in P301S Tia1 +/mice, the behavioral deficit was rescued to normal working memory levels ( Fig. 4a ); TIA1 reduction had no effect in non-transgenic mice (Fig. 4a ). We also employed a second behavioral task, the novel object recognition (NOR) task, to assess recognition memory and independently confirm the beneficial effect of TIA1 reduction in a separate domain of cognitive function. As expected, 6-month-old P301S Tia1 +/+ mice were not able to distinguish between novel and familiar objects, indicating an impairment in recognition memory (Fig. 4b ). In contrast, P301S Tia1 +/mice exhibited greater than 65% preference indices for the novel object, confirming a restoration of functional recognition memory to levels similar to those seen in non-transgenic animals (wild-type (WT) Tau Tia1 +/+ and WT Tau Tia1 +/-; Fig. 4b ). Notably, P301S Tia1 +/+ and P301S Tia1 +/mice did not differ in the amount of locomotor activity in the SAT or open field (OF) tasks, indicating that their improved memory performance could not be attributed to differences in locomotor or anxiety-like behaviors ( Fig. 4c and Supplementary Figs. 5 and 6a-d). While both SAT and NOR tasks depend in part on hippocampal function, the SAT depends on additional circuitry, including the prefrontal cortex, basal forebrain and dorsal striatum 19 , whereas NOR more selectively depends on the hippocampus and perirhinal cortex 20 . The improvement in behavior obtained from these two distinct memory tasks suggests that TIA1 reduction might confer widespread protection against neurodegeneration. These results suggest that RBPs exert an especially important influence on tau-mediated perturbations related to cognition, which is the primary clinical feature of tauopathies.
As our data also suggest that TIA1 reduction protects against tau-mediated neurodegeneration in vivo ( Fig. 3) , we sought to determine whether TIA1 reduction could increase the lifespan of PS19 mice. A previous study found that PS19 mice die prematurely due to motor ataxia and hindlimb paralysis, with a reported median survival of 9 months and 80% mortality by 12 months of age 16 . . d, Representative images of cortical layers I through VI in 9-month-old non-transgenic and P301S cerebral cortex (primary somatosensory cortex, S1). Scale bar, 100 μ m. Red asterisks and arrowheads denote the start of layer II and end of layer III, respectively. e, Quantification of average layer II/III cortical thickness in S1 from d. **P < 0.01 by two-way ANOVA with Tukey's post hoc tests (n = at least 11 per group). Error bars denote mean ± s.e.m.
Our cohort of P301S Tia1 +/+ mice recapitulated this lifespan phenotype ( Fig. 4d ). In contrast, the P301S Tia1 +/mice exhibited a striking increase in lifespan (mean lifespan = 11.3 months, n = 23, compared to 9.3 months for P301S Tia1 +/+ , n = 20), with 43.5% surviving to 12 months of age without exhibiting overt symptoms of disease (for example, ataxia, hind limb weakness, hunched posture; Fig. 4d and Supplementary Table 1 ). Further, 5 of 21 (23.8%) P301S Tia1 +/mice that were allowed to age until 15 months survived compared to none (0.0%) of the P301S Tia1 +/+ mice ( Fig. 4d and Supplementary  Table 1 ). As expected, all of the non-transgenic mice in this study (WT Tau Tia1 +/+ , n = 12; WT Tau Tia1 +/-, n = 16) survived to 12 months of age without evidence of motor or neurological symptoms (data not shown). Thus, TIA1 reduction extended median lifespan by 21.5% in PS19 mice. These findings indicate that TIA1 reduction confers robust behavioral protection against tau-mediated neurodegeneration and premature mortality in PS19 mice.
TIA1 reduction initially decreases tau phosphorylation.
Tau is hyperphosphorylated in AD and FTD-tau, with hyperphosphorylation leading to tau aggregation and subsequent pathology. We compared the age-dependent accumulation of phosphorylated tau in P301S Tia1 +/+ and P301S Tia1 +/mice by IHC. As expected, P301S Tia1 +/+ mice accumulated detectable levels of CP13 (S202)and AT8 (S202/T205)-phosphorylated tau in the hippocampus by 3 months of age ( Supplementary Fig. 7 ). Little to no phosphorylated tau was observed in the cortex or cerebellum of P301S Tia1 +/+ mice at 3 months of age, consistent with the expected progression of disease in PS19 mice (data not shown). In contrast, P301S Tia1 +/mice exhibited reduced levels of CP13-and AT8-phosphorylated tau in the hippocampus (CA1, CA3) compared to P301S Tia1 +/+ mice at 3 months of age ( Supplementary Fig. 7b ,c), suggesting that TIA1 reduction delays the onset of pathology in PS19 mice. This reduction of tau pathology in young P301S Tia1 +/mice is consistent with our prior short-term studies using cultured neurons 13 . We then determined how TIA1 reduction affected tau phosphorylation at later stages of disease by measuring the levels of AT8-, CP13-and PHF1-phosphorylated tau at 6 and 9 months of age. Unexpectedly, TIA1 reduction led to increased immunofluorescence for AT8-and CP13-phosphorylated tau at 6 and 9 months ( Supplementary Fig. 7d ). TIA1 reduction also increased the number of PHF1 + inclusions in LEnt and CA3 at 9 months of age ( Fig. 5a,b ). While almost 20% of PHF1 + inclusions co-localized with cytoplasmic TIA1 in P301S Tia1 +/+ mice, less than 5% of PHF1 inclusions contained TIA1 in P301S Tia1 +/mice ( Fig. 5c,d ). The P301S Tia1 +/mice also showed a striking rescue of TIA1 nuclear localization, with TIA1 being largely restricted to the nucleus even in PHF1 + neurons ( Fig. 5c ). Immunoblot analysis of total brain lysates confirmed that levels of CP13-and PHF1-phosphorylated tau were increased in aged P301S Tia1 +/compared to P301S Tia1 +/+ mice ( Supplementary Fig. 8a -c); total tau levels were also slightly elevated ( Supplementary Fig. 8d ). Thus, TIA1 reduction initially decreased the level of phosphorylated tau pathology in PS19 mice but exhibited an age-dependent increase in phosphorylated tau at later stages of disease.
TIA1 reduction accelerates NFT accumulation while decreasing levels of soluble tau oligomers.
Tau phosphorylation leads to aggregation of tau proteins 21, 22 . Consistent with the age-dependent increases in tau phosphorylation, an increase in NFTs was also apparent in P301S Tia1 +/mice. As expected, 9-month-old P301S Tia1 +/+ mice developed widespread Gallyas silver-and thioflavine S (ThioS)-positive tangles throughout the hippocampus and temporal cortex ( Fig. 5e-h ). P301S Tia1 +/mice exhibited increased numbers of Gallyas silver-positive neurons in both the frontal (primary motor area, M1) and temporal (LEnt) cortices ( Fig. 5f ); TIA1 reduction also increased the level of ThioS fluorescence ( Fig. 5g ,h). The number of Gallyas silver-positive tangles did not differ between P301S Tia1 +/+ and P301S Tia1 +/mice in the CA3 region of the hippocampus, perhaps resulting from a 'ceiling effect' caused by the advanced level of pathology in CA3 relative to other brain areas in this model ( Fig. 5f ). Although they displayed equal numbers of NFTs in CA3 at 9 months of age, there was no relationship between tangle burden and neuronal loss in either P301S Tia1 +/+ or P301S Tia1 +/mice (r 2 = 0.07; Supplementary Fig. 9 ). Thus, the neuroprotection associated with TIA1 reduction in PS19 mice occurred independently from NFTs, consistent with previous studies suggesting that NFTs are not the direct cause of neuronal loss in tauopathies [23] [24] [25] .
The improved functional phenotype in P301S Tia1 +/mice, despite increased tau pathology, led us to hypothesize that TIA1 reduction alters the structural or biochemical properties of tau aggregates, producing tau species that are less toxic. This possibility seemed particularly plausible given the recent findings that neurons containing NFT-like inclusions remain functional and that different strains of tau aggregates exhibit distinct patterns of propagation and pathophysiology when injected into tauopathy mice [23] [24] [25] [26] [27] . Biochemical fractionation studies identify tau species with distinct structural properties that are apparent upon separation of Tris-buffered saline (TBS)-extractable (S1), sarkosyl-soluble (S3) and sarkosyl-insoluble (P3) fractions 28 . A second, high-speed spin of the S1 fraction yields a supernatant (S1c) and insoluble pellet (S1p) fraction. The insoluble material (S1p) from the TBS-extractable fraction contains oligomeric tau species that correlate with neurodegeneration in rTg4510 mice, while the P3 fraction contains mostly fibrillar, hyperphosphorylated (CP13 + PHF1 + ) tau 29 . Similar approaches using 6-and 9-month-old P301S Tia1 +/+ and P301S Tia1 +/mice showed that tau progressively accumulates in both the S1p and P3 fractions of P301S Tia1 +/+ mice ( Fig. 6a-c ), suggesting accumulation of oligomeric tau and NFTs, respectively. In the S1p fraction, immunoblotting for total tau identified predominant bands under nonreducing conditions at 64, 140 and 170 kDa, confirming the presence of both tau monomers and oligomers in this fraction (Fig. 6a ). Unexpectedly, while TIA1 reduction increased NFTs ( Fig. 5 ) and showed a concomitant increase in the level of tau in the P3 fraction, TIA1 reduction greatly decreased the level of all tau isoforms detected in the S1p fraction ( Fig. 6a,b ). Enzyme-linked immunosorbent assays (ELISAs) performed using non-denaturing conditions with antibodies that recognize pathological conformations of misfolded tau (TNT1, recognizing exposure of the phosphatase-activating domain (PAD)) and oligomeric tau (TOC1) showed reduced levels of misfolded and oligomeric tau in the S1 fraction ( Supplementary Fig. 10 ) 30 . This result suggests that TIA1 reduction shifts the pathway of tau aggregation, preventing the accumulation of oligomeric tau while promoting the accumulation of fibrillar tau.
TIA1 drives the accumulation of tau oligomers. Since aggregation of tau oligomers in the S1p fraction was sensitive to TIA1 reduction, we next investigated whether other RBPs co-aggregated with tau oligomers. We analyzed the S1p ('tau oligomer') cortical fraction by OrbiTrap liquid chromatography tandem mass spectrometry to determine whether this biochemical fraction is enriched for other RBPs. As expected, the level of tau protein detected in the S1p fraction was significantly elevated in P301S Tia1 +/+ compared to nontransgenic (WT Tau Tia1 +/+ ) cortex (Supplementary Table 2 ). We then used the Database for Annotation, Visualization and Integrated Discovery (DAVID) 31 to analyze the proteins identified in the S1p fraction of P301S Tia1 +/+ cortex by liquid chromatography tandem mass spectrometry. These studies revealed statistically significant enrichment (false discovery ratio < 0.05) for annotations related to RNA metabolism ( Supplementary Fig. 11a ). In comparison to WT mice, poly(A) RNA binding was the most significant gene ontology annotation term enriched among proteins that accumulated in the S1p fraction of P301S Tia1 +/+ compared to non-transgenic mice ( Supplementary Fig. 11a and Supplementary Table 2 ; false discovery ratio = 2.25 × 10 −5 ). Immunoblot analysis confirmed an agedependent accumulation of RBPs in both the S1p and P3 fractions of P301S Tia1 +/+ mice ( Supplementary Fig. 11b ). TIA1 reduction selectively decreased the level of the RBPs PABP and DDX6 in the S1p fraction but not in the P3 fraction ( Supplementary Fig. 11b ). Taken together, these results suggest that RBPs co-accumulate with tau oligomers in a manner dependent on TIA1. We examined whether TIA1 directly influences tau aggregation. Fibrillization of tau and phospho-tau was studied by thioflavine T fluorescence; phosphorylated 0N4R tau was prepared by reaction with glycogen synthase kinase 3-β (GSK3β ) for 30 min and validated by immunoblot with PHF1 antibody. Fibrillization of tau was examined by incubating 10 μ M tau or GSK3β -phosphorylated tau (pTau) ± 2 μ M TIA1, total RNA (20 ng/μ L) and dextran sulfate (0.04 μ g/μ L) in the aggregation reaction mixture. Tau fibrillization was significantly reduced in the presence of TIA1 (Fig. 7a ). TIA1 also produced significantly more tau oligomers, as quantified by ELISA using the TOC1 anti-oligomeric tau antibody (Fig. 7b ). Analysis of the aggregation mixtures by electron microscopy showed that the presence of TIA1 significantly disrupted fibrillization of tau, producing significantly shorter fibril lengths than similar mixtures incubated without TIA1 (Fig. 7c,d and Supplementary Fig. 12 ). We used immunogold to double-label the 48-h pTau assembly reactions with antibodies to TIA1 and either Tau13 (to visualize all tau aggregates, including fibrils) or TOC1 (to visualize prefibrillar tau oligomers). Analysis by electron microscopy confirmed the presence of both Tau13 + tau fibrils and TOC1 + tau oligomers ( Supplementary Fig. 13 ).
No TOC1 or TIA1 immunostaining was observed on long fibrillar tau aggregates ( Supplementary Fig. 13 ). In contrast, TIA1 co-labeled prefibrillar tau aggregates also positive for TOC1 ( Supplementary  Fig. 13 ), suggesting a selective association of TIA1 with tau oligomers. The specificity of TOC1 was validated by the absence of labeling of cortical tissues from WT mice, which contrasted with robust reactivity in P301S Tau mice ( Supplementary Fig. 14) .
Discussion
Dysfunction of RBPs is implicated in multiple neurodegenerative diseases 32, 33 . Our results now show that TIA1 and other RBPs accumulate in concert with oligomeric tau in an animal model of tauopathy. Notably, reducing TIA1 led to the selective reduction of tau oligomers, with a corresponding increase in sarkosyl-insoluble tau fibrils. This reduction in oligomeric tau occurred in parallel with strong neuroprotection, behavioral rescue and increased longevity in the P301S Tia1 +/mice, demonstrating an important role for TIA1 in directing the pathway of tau aggregation and the resulting neurodegeneration.
The classic model for protein aggregation in neurodegenerative diseases posits that proteins with disordered or hydrophobic regions inappropriately aggregate through a process of random association that has little or no biological function 34 . This model might well reflect the mechanism driving the aggregation of amyloids that accumulate in the extracellular compartment, such as β -amyloid. However, recent discoveries support an alternative model reflecting the biological functions of RBPs and many nuclear proteins. These proteins all contain low-complexity domains whose biophysical properties promote aggregation under normal physiological conditions [9] [10] [11] [12] 35 . At high concentrations, recombinant RBPs self-aggregate, forming liquid-like droplets that phase-separate and cycle between liquid and solid states in response to temperature 9-12 . This process leads to formation of membraneless organelles, including SGs, transport granules and P-bodies, and nuclear structures, such as the nucleolus and promyelocytic leukemia (PML) bodies 4, [36] [37] [38] .
We recently demonstrated that tau acts as part of the translational stress response to promote formation of SGs, which allows the neuron to adapt its pattern of protein synthesis to cope with stress 13 . Internalization of extracellular tau, such as might occur with propagation, also appears capable of inducing SGs 39 . Somatodendritic mislocalization would allow tau to interact with RBPs, RNA and ribosomes, providing a mechanism through which tau can inhibit protein synthesis 40 . Potential mechanistic underpinnings for the interaction of tau with SGs was recently provided by the discovery that tau undergoes liquid-liquid phase separation in the presence of RNA 41 . Thus, the abundance of RNA in SGs (and potentially other RNA granules) might be sufficient to stimulate oligomerization and/or liquid-liquid phase-separation of tau. This combined work presents a biological explanation for why neurons would have tau mislocalize to the somatodendritic arbor and aggregate during stress. We also observed that the association of tau with SGs promotes its aggregation 13 . These accumulating observations raise the possibility that SGs and perhaps other RNA granules contribute to the pathophysiology of tauopathy.
Because SGs have not been well characterized in vivo in the context of disease, we refer to the in vivo equivalent as pSGs. The dynamics and full composition of the pSGs observed in the P301S mice remain to be determined, which means that the nature of pSGs could differ from classic SGs. Co-localization of tau with the SGs is a parsimonious definition of a pSG that would be prominent in tauopathy. In addition, both pSGs and tau pathology might evolve with time, raising the possibility that the composition might differ based on disease stage.
The current study directly addresses the process of tauopathy in the aging brain in vivo. We discovered that the relative accumulation of tau oligomers and fibrils can be regulated by TIA1, suggesting a more general role for RBPs in this process. The process of tau aggregation is known to proceed through multiple steps, including misfolding, oligomerization and fibrillization, but how RBPs might interact with these intermediates is unknown 42 . Using electron microscopy, we demonstrated the unexpected finding that TIA1 stabilizes prefibrillar tau aggregates and inhibits their further assembly into large fibrils. We also used mass spectrometry to analyze the oligomeric fraction from diseased brains and observed a striking enrichment of RBPs in P301S Tia1 +/+ compared to wild-type or P301S Tia1 +/samples. This demonstrates that the association of tau with RBPs is likely not limited to TIA1, which is consistent with our prior network analysis showing multiple proteins whose association with TIA1 was dependent on tau 13 . These results now allow us to extend the model of tau aggregation to propose that tau oligomers selectively associate with RBPs, raising the possibility that tau oligomers might be an active species in promoting pSGs and the translational stress response. The putative importance of tau oligomers in the interactions with TIA1 and RNA is supported by a recent study demonstrating that tau phase separates in the presence of RNA 41 . The concentrations of RNA that we used were significantly lower, but the presence of TIA1 in our mixtures might allow for local concentrations of RNA, much like what might be predicted to occur in a SG. Neurodegenerative diseases related to aging arise in vivo only after an extended period of time and evolve at a slower pace than in vitro studies, an issue that highlights the inherent challenge of translating findings from simplified models with recombinant proteins or cultured cells to mouse models and human patients. We show that reducing TIA1 in PS19 mice elicits a striking reduction in an otherwise over-abundant pSG response. Notably, reducing TIA1 also correlated with an increase in neuronal survival, improvements in memory and an extension of lifespan. The striking reduction in tau oligomers and corresponding increase in tau fibrils associated with TIA1 haploinsufficiency suggest that the RBPs associated with pSGs (including TIA1) stabilized tau oligomers, leading to their accumulation and subsequent pathological responses ( Supplementary Fig. 15 ). In absence of the pSG response, the overexpressed tau in these brains accumulated as tau fibrils, through a process that likely transitions rapidly through the oligomer stage or proceeds through an alternative mechanism. AD and other tauopathies do not arise from overexpression of tau, suggesting that tau aggregation in humans might be less driven by mass action than in animal models. The absence of a pSG response also correlates with behavioral improvements in the PS19 mice, suggesting a scenario in which the association of tau with pSGs might exert a larger role on neurodegeneration in humans, increasing the potential for therapeutic utility.
RBPs such as TIA1 have multiple roles in the cell, regulating RNA localization and utilization in the soma and dendritic arbor, as well as in processes such as splicing and RNA polymerase procession in the nucleus 43, 44 . The pleiotropic roles of TIA1 raise the possibility that TIA1 reduction protects against tauopathy through multiple mechanisms. A full mechanistic understanding will likely be elucidated as research on this pathway progresses.
This work presents tauopathy in a new light, placing it on the spectrum of diseases associated with RBPs. FTD is thought to exist as a continuum with ALS. Many of the genes that cause ALS also cause or appear as pathological species in FTD 37 . We recently demonstrated that somatodendritic tau regulates RBP biology in cultured neurons, suggesting that tau is a functional member of this cohort of proteins 13 . The current work demonstrates that RBPs regulate the pathophysiology of tau, suggesting a new model for the genesis of tauopathy. Our results provide a model that begins to link the rapid biophysics of liquid-liquid phase-separation with the course of neurodegenerative disease, which can take months to years. This evolving model provides a mechanistic site for entry of RBPs into the process of tau aggregation and subsequent tau-mediated neurodegeneration, which opens up many additional targets for therapeutic investigation in the treatment of AD and other tauopathies.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41593-017-0022-z.
Animals. Tia1 -/mice (B6.129S2(C)-Tia1 tm1Andp /J) were generated by Anderson and colleagues and obtained from Harvard University, Dana Farber Cancer Institute 17 ; these mice had previously been backcrossed for 10+ generations to the C57BL/6 J inbred strain. PS19 (B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J, stock #008169) and C57BL/6 J (stock #000664) mice were purchased from Jackson Laboratory 16 . All animals were housed in IACUC-approved vivariums at Boston University School of Medicine. To generate colonies of P301S Tia1 +/+ and P301S Tia1 +/mice, PS19 mice were bred with Tia1 -/mice to produce pups that were heterozygous for the endogenous mouse Tia1 allele (Tia1 +/-) and either transgenic (P301S +/-, or 'P301S Tau') or non-transgenic (P301S -/-, or 'WT Tau') for human P301S MAPT. Transgenic (P301S +/-Tia1 +/-) and non-transgenic (P301S -/-Tia1 +/-) pups from the F1 generation were then bred to produce littermate control P301S Tia1 +/+ and P301S Tia1 +/mice on identical genetic backgrounds, which were then used in the experiments described in this manuscript. This breeding scheme generated the expected Mendelian ratios of offspring (25% Tia1 +/+ , 50% Tia1 +/and 25% TIA1 -/-); however, before extensive backcrossing, early generations of pups produced fewer mice than expected with the TIA1 -/genotype. Thus, analysis of P301S TIA1 -/mice was excluded from this study due to insufficient sample sizes. Unless noted otherwise, equal numbers of male and female mice were used in all experimental comparisons; no statistically significant differences with respect to sex were observed in any of the experiments described in this study (data not shown). Due to the necessity of genotyping the mice, randomization was not possible for group selection. However, whenever possible, experimenters were blinded to the genotype of each mouse, which was then decoded using the ear-tag identification numbers after data collection and analysis. Mice were aged 3, 6 and 9 months for analysis by the behavioral, biochemical and histological approaches described below. Sample sizes were chosen based on prior publications using these mice 16 . The Animal Care and Use Committee for Boston University Medical Center approved the animal protocols used in this work.
Genotyping. Tail snips from ear tagged mice were digested using Proteinase K, and the DNA was purified using the Qiagen DNeasy kit according to manufacturer's instructions (cat# 69504). The human 1N4R P301S transgene was amplified using the following primers:
hTau: forward = GGG GAC ACG TCT CCA CGG CAT CTC AGC AAT GTC TCC; reverse = TCC CCC AGC CTA GAC CAC GAG AAT using the cycling parameters specified by The Jackson Laboratory (https://www2. jax.org/protocolsdb/f?p= 116:5:0::NO:5:P5_MASTER_PROTOCOL_ID,P5_JRS_ CODE:25393,008169). Mice were also genotyped both for the wild-type Tia1 allele (WT mTia1 forward: CTC CTT TAC CAG GAC CAC CA; reverse: ACC ATG GGG AAA AGG AGG TA) and for a frame-shifted mutant allele that does not encode TIA1 protein (mutant mTia1 forward; CTC CTT TAC CAG GAC CAC CA; reverse: GCC AGA GGC CAC TTG TGT AG), also using the cycling parameters specified by The Jackson Laboratory (https://www2.jax.org/protocolsdb/f?p= 116:5:0::NO:5:P5_MASTER_PROTOCOL_ID,P5_JRS_CODE:23469,009248). Amplified DNA was separated by electrophoresis in a 2% agarose gel and visualized with 1% ethidium bromide using a BioRad imager.
Behavioral analysis. All behavioral analyses used equal numbers of male and female mice and were performed at 6 months of age, before the onset of the neuromuscular symptoms of disease (i.e., ataxia, hind limb weakness/paralysis). For the open field (OF) assay, mice were placed in a light-and sound-proof chamber (22 cm wide × 42 cm long) and recorded for 30 min using infrared cameras (Swann Security, Victoria, Australia). Total locomotor activity, center time, mean speed and freezing behaviors, amongst other parameters, were automatically measured using ANY-maze behavioral tracking software (Stoelting, Wood Dale, IL). For the Y-maze spontaneous alternation task (SAT), animals were placed in an opaque, Y-shaped maze, with three arms of equal length (15 inches (38.1 cm) each) that diverged at equal angles, and recorded for 10 min. The total number and sequence of arm entries over the test period was scored by two blinded observers. A successful alternation was defined as consecutive entries into all three arms without returning to a previously visited arm. Thus, the maximum number of alternations was the total number of arm entries minus two, and the correct alternation percentage was calculated as (actual alternations/maximum alternations) × 100. For the novel-object recognition (NOR) test, animals were habituated to the testing chambers for 30 min for 2 consecutive days before testing day. The testing chambers were rectangular (22 cm wide × 42 cm long) apparatuses completely covered on the outside in four different patterns of construction paper to make the environment opaque and to allow the mice to spatially orient themselves in the apparatus. The four patterns used for the wall cues were blank (white), polka dots, horizontal bars and vertical bars (all black and white). On testing day, animals were placed in the chamber and allowed to explore two identical objects for 5 min (exploration phase). Ninety minutes later, the animals were returned to the testing chamber with one of the two objects replaced with a novel object. The exploratory behavior of the animals was recorded for 5 min using infrared cameras (Swann Security, Victoria, Australia). The objects used in the study were T-25 cell culture flasks filled with sand and multicolored rectangular Lego stacks, as described previously 45 . All experimental factors, including the type and location of the novel object, were counterbalanced throughout the experiment. Mice that did not explore the objects for at least 10 s during the exploration phase were excluded from analysis in the testing phase. The amount of time spent exploring the familiar and novel objects, determined by head placement within 0.5 cm of each object, was automatically measured using ANY-maze behavioral tracking software (Stoelting). For the survival study, animals were assessed daily starting at 7 months of age by the veterinary staff of the Boston University Animal Science Center, who were blinded to the genotype of the animals. The endpoint criterion was defined as at least one of the following: dragging or paralysis of two or more limbs, postural instability/inability to feed or greater than 10% loss in body weight.
Tissue processing. Animals were deeply anesthetized and perfused with ice-cold phosphate buffered saline (PBS), followed by brain dissection. The left hemisphere was fixed in 4% paraformaldehyde/PBS for 24 h, and then transferred to 30% sucrose/PBS solution for 48 h before freezing in OCT media for cryosectioning. We used a fixation time of 24 h because prior optimization experiments for TIA1 (and other RBP) immunohistochemistry demonstrated that fixation for longer periods reduces the ability to detect inclusions containing TIA1. Brains were cut into 40-µ m coronal sections and stored at − 20 °C in 30% glycerol/30% ethylene glycol/ PBS solution until day of staining. From the right hemisphere, the cerebellum, hippocampus, striatum and cerebral cortex tissues were separately dissected and flash frozen on dry ice before biochemical analysis as described below.
Histology. Nissl and Gallyas silver staining were performed on 40-µ m free-floating sections using the FD Cresyl Violet (cat# PS102-01) and FD NeuroSilver Kit II (cat# PK301A) kits from FD NeuroTechnologies, according to the manufacturer's instructions. For neuron number studies, the number of Nissl + neurons per field was counted by three blinded observers and the average was determined. Neuronal loss was also determined by a secondary method, NeuN immunohistochemistry (see below), and quantified using Imaris Bitplane automated imaging software. For layer II/III cortical thickness studies, Nissl-stained sections were imaged at 10× magnification using a brightfield microscope. The length between the most superficial point of layer II and the deepest point of layer III was measured using a Zen Blue microscope and image analysis software. At least 5 measurements were taken per image, 3 images per mouse (n = 6 mice per group). For thioflavine S (ThioS) staining, 40-µ m sections were mounted onto glass microscope slides and allowed to completely dry. Slides were washed sequentially in 70% and 80% ethanol for 1 min each before incubating in 1% ThioS/80% ethanol solution for 15 min. Sections were then sequentially washed in 80% and 70% ethanol for 1 min each, followed by two rinses in distilled water. Slides were mounted in Prolong Gold antifade reagent and stored in the dark until imaging.
Immunohistochemistry. For immunohistochemistry (IHC), 40-µ m sections prepared as described above were immunostained, free-floating in 12-well plates. Sections were washed in Tris-buffered saline (TBS), followed by permeabilization in TBS supplemented with 0.05% Triton X-100 (TBS-T) and three washes of 10 min each. Sections were then incubated in citric acid-based antigen unmasking solution (Vector Laboratories, cat# H-3300) for 1 h at 70 °C. Following antigen retrieval, sections were cooled to room temperature (RT, 20-22 °C), washed three times in TBS-T and incubated in blocking buffer (TBS-T supplemented with 5% normal donkey serum and 1% bovine serum albumin (BSA)) at RT for 2 h. Sections were then incubated in primary antibody solutions diluted in blocking buffer for 48 h at 4 °C. The primary antibodies used were as follows: AT8 (1:100, ThermoFisher Scientific, cat# MN1020), CP13 and PHF1 (1:100, generously provided by P. Davies (Feinstein Institute, Manhasset, NY), TIA1 (1:300, Abcam cat# ab40693, lot GR151575-3), PABP (1:300, Abcam cat# ab21060), Staufen (1:200, Abcam cat# ab73478), DCP1A (1:200, Novus cat# H00055802-MO6), neurofilament (1:1,000, EMD Millipore cat# AB5539), NeuN (1:1,000, EMD Millipore cat# ABN78) and synaptophysin (1:300, SantaCruz Biotechnology cat# sc-17750). After 48 h, sections were washed four times in TBS-T and incubated in donkey Alexa Fluor-488/594-conjugated secondary antibodies (Jackson ImmunoResearch) diluted 1:500 in blocking buffer for 2 h at RT. (Detailed information for all primary and secondary antibodies, including validation and catalog numbers, can be found in the Life Sciences Reporting Summary.) After incubation in secondary antibodies, the sections were washed twice in TBS-T, followed by 20-min incubation in DAPI nuclear stain (1:20,000 in TBS-T) and two final washes in TBS-T. Sections were then mounted on microscope slides, immersed in 1% Sudan Black B solution for 15 min to quench endogenous lipofuscin autofluorescence, rinsed twice in 70% ethanol and coverslipped using Prolong Gold antifade reagent for imaging using epifluorescence and/or confocal microscopes. All staining steps were performed with gentle agitation. Plates were covered in aluminum foil for all steps following addition of secondary antibodies to prevent photobleaching of fluorophores.
Biochemical fractionation. Hippocampus and cortex tissues were homogenized in 10× v/w (μ L:mg) Hsiao TBS buffer (50 mM Tris, pH 8.0, 274 mM NaCl, 5 mM KCl) supplemented with protease and phosphatase inhibitor cocktails (Roche, cat# 05892791001 and cat# 04906837001), as described previously. We ultracentrifuged 100 mg cortical and 50 mg hippocampal homogenates at 28,000 rpm at 4 °C for 20 min. The supernatant (S1) fractions were ultra-centrifuged a second time at 55,000 rpm at 4 °C for 20 min to separate the TBS-extractable supernatant (S1c) and pellet (S1p) fractions. S1p pellets were resuspended in 4× volume of TE buffer, relative to the starting weight of the tissue homogenate. Next, the pellet from the first spin (P1) was homogenized in 5× v/w Buffer B (10 mM Tris, pH 7.4, 800 mM NaCl, 10% sucrose, 1 mM EGTA, 1 mM PMSF) using a micro-centrifuge pestle and then ultra-centrifuged at 22,000 rpm at 4 °C for 30 min. Detergent was then added to the supernatant (S2) fraction to yield a final concentration of 1% sarkosyl, followed by incubation at 37 °C on a thermomixer for 1 h. The samples were then ultra-centrifuged at 55,000 rpm at 4 °C for 1 h to yield the sarkosylsoluble (S3, supernatant) and sarkosyl-insoluble (P3, pellet) fractions. Finally, RIPA buffer was added to the remaining unused brain homogenates to a final concentration of 50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.1% SDS and 5 mM EDTA. The S1p, S3, P3 and total (RIPA-soluble) fractions from the same starting tissues were then analyzed by SDS-PAGE as described below. S1p fractions were also shipped to the UMASS Proteomics and Mass Spectrometry facility and analyzed by OrbiTrap liquid chromatography tandem mass spectrometry, as described previously 13 .
Immunoblot. Reducing and nonreducing protein samples were separated by gel electrophoresis and transferred to nitrocellulose membranes using the Bolt SDS-PAGE system (Life Technologies). Membranes were blocked in 5% nonfat dry milk (NFDM) in TBS supplemented with 0.025% Tween-20 (TBS-T) for 1 h at RT, followed by incubation overnight at 4 °C in primary antibody diluted in 5% bovine serum albumin/TBS-T. Primary antibodies used were as follows: Tau5 (1:1,000), Tau13 (1:25,000), PHF1 (1:500) and CP13 (1:500) anti-tau antibodies (the PHF1 and CP13 antibodies were generously provided by P. Davies; detailed information for all primary and secondary antibodies, including validation and catalog numbers, can be found in the Life Sciences Reporting Summary); TIA1 (1:500, Santa Cruz Biotechnology, sc-1751), total α -tubulin (1:5,000), PABP (1:1,000, Abcam cat# ab21060) and DDX6 (1:500, Bethyl Labs cat# A300-460A). Membranes were then washed three times with TBS-T and incubated in HRPconjugated secondary antibodies (Jackson ImmunoResearch) diluted in 1% NFDM/TBS-T at RT for 1 h. After incubation in secondary antibody, membranes were washed three times in TBS-T and developed using SuperSignal West Pico Chemilluminescent ECL substrate (ThermoFisher Scientific, cat# 34080).
ELISAs. Capture antibodies (Tau5, TNT1 and TOC1) were diluted to a final concentration of 2 ng/µ L in phosphate buffered saline (PBS) and adsorbed to Nunc Maxisorp 96-well plates (Cole Palmer, cat# EW-01928-08) for 1 h. Plates were washed 4× in PBS, blocked for 1 h with 5% NFDM/PBS and washed again 4× in PBS. For non-denaturing analysis of S1 fractions from 9-month-old PS19 cortex, 20 µ g/well samples were diluted in PBS and added to each well in triplicate. Known concentrations of recombinant human tau (WT 0N4R) were used to generate a standard curve. Samples were incubated for 1.5 h at RT, washed 4× in PBS and incubated for 1 h with detection antibody (rabbit anti-R1 total tau) diluted 1:10,000 in 5% NFDM/PBS. Plates were washed 4× in PBS followed by incubation with HRP-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch) diluted 1:5,000 in 5% NFDM/PBS for 1 h. (Detailed information for all antibodies, including validation and catalog numbers, can be found in the Life Sciences Reporting Summary.) Plates were washed 4× in PBS and incubated in o-phenylenediamine (OPD) solution (1 mg/mL OPD in 0.05 sodium phosphate, pH 5.0, 0.05 M citric acid and 1% hydrogen peroxide) for 15 min at RT. Reactions were stopped using 2.5 M sulfuric acid, and the absorbance was measured at 490 nm.
Microtubule binding assay. Frozen cortex tissue was homogenized in 10 × v/w (μ L/mg) RAB buffer (0.1 M MES, pH 6.8, 0.5 mM MgSO 4 , 1 mM EGTA, 2 mM DTT, 4 M glycerol, 2 mM GTP, 0.1% Triton X-100). We ultra-centrifuged 50 mg homogenate at 50,000 rpm at 30 °C for 40 min. The supernatant (S, unbound) fraction was removed to a new micro-centrifuge tube and stored at − 80 °C. Pellet (P, microtubule-bound) fractions were resuspended in urea buffer (30 mM Tris-HCl, pH 8.4, 8 M urea, 1% CHAPS). We then analyzed 10 µ L each of the supernatant and pellet fractions by SDS-PAGE.
Thioflavine T aggregation assay. Recombinant tau and TIA1 were prepared according to standard methods, with purity assessed by Coomassie staining after PAGE and by immunoblot. We mixed 10 μ M recombinant 0N4R tau ± 2 μ M recombinant TIA1 in reaction buffer (10 mM HEPES, 10 mM NaCl, 1 mM DTT, 20 ng/μ L RNA, 5 μ M thioflavine T) ± 0.04 μ g/μ L dextran sulfate (DS); negative control samples lacked RNA and DS. Fluorescence was monitored (440 ex/482 em nm) for 48 h at 37 °C with continual shaking. Tau was phosphorylated with GSK3β (25 U/μ L; with 1 mM ATP) for 30 min, whereupon the reaction was quenched with 50 mM LiCl.
Electron microscopy. Mixtures of tau aggregates were prepared using the ThioT aggregation assay described above. Forty-eight-hour reaction mixtures with or without TIA1 were adsorbed for 2 min onto formvar/carbon-coated nickel-mesh grids, washed twice with distilled water (dH 2 0), treated with 2% uranyl acetate, washed 4× with dH 2 0 and imaged at 80 kV using a JEOL JEM 1011 with a digital camera (Gatan). For double immunogold labeling, grids were rinsed 4× in TBS, blocked for 30 min in block buffer (1% BSA/TBS supplemented with 2.5 µ g/mL gelatin, 2% BSAc) and incubated for 2 h in rabbit anti-TIA1 (1:500, Abcam cat# ab40693) and mouse anti-tau (Tau13 or TOC1, 1:1,000) antibodies diluted in block buffer. After 2 h, the grids were washed 4× in TBS before incubation for 1 h in 15-nm (anti-rabbit) and 6-nm (anti-mouse) gold particle-conjugated secondary antibodies diluted 1:50 in block buffer. (Detailed information for all primary and secondary antibodies, including validation and catalog numbers, can be found in the Life Sciences Reporting Summary.) After 1 h, the grids were washed 4× in TBS, then twice with dH 2 O before treatment with 2% uranyl acetate. Grids were then washed a final 4× in dH 2 O and imaged as described above.
Image analysis.
Images were analyzed for total fluorescence, co-localization, puncta and cell numbers, as appropriate, using Imaris Bitplane and ImageJ image analysis software. For quantification of stress granules, PABP and TIA1 colabeled sections were thresholded (TIA1 fluorescence intensity above 69.6, PABP intensity above 9.7) with nuclear masking using DAPI. The number of cytoplasmic (defined by exclusion from DAPI + nuclei) puncta with diameter greater than or equal to 2 µ m co-positive for both TIA1 and PABP were counted and divided by the total number of DAPI + nuclei per image. For quantification of nuclear versus cytoplasmic immunofluorescence, images were processed as described above, and the total immunofluorescence of TIA1 within (nuclear) and outside (cytoplasmic) of DAPI + nuclei was calculated and divided by the total number of DAPI + cells per image. Statistical analysis was performed using GraphPad Prism data analysis software.
Statistical analysis. The sample sizes for the experiments were chosen based on prior publications using these mice, which defined the expectations for the effect sizes and variance 16 . The statistical tests performed with data assumptions are described in Supplementary Table 3 . Statistical analyses were performed using the GraphPad Prism data analysis software. We used t tests for samples with only two groups. For samples with multiple groups, one-and two-way between-subjects ANOVA with Tukey's post hoc testing was performed. No data points were excluded. For in vitro experiments (Fig. 7) , there are 3-5 replications. For IHC and immunoblotting, all experiments include independent samples for replication. Replication was not possible for the behavioral or survival studies.
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary.
Data availability statement. All data generated or analyzed during this study are included in this published article (and its associated Supplementary Information). In particular, the proteomics data on the S1p fraction are presented in Supplementary Table 2 
Data exclusions
Describe any data exclusions. No data points were excluded from the analyses. However, for the novel object recognition test, note that mice that did not explore the objects for at least 10 s during the exploration phase were excluded from analysis in the testing phase.
Replication
Describe whether the experimental findings were reliably reproduced.
For in vitro experiments ( Fig. 7) there are 3-5 replications. For IHC and immunoblotting all experiments include independent samples for replication. Replication was not possible for the behavioral or survival studies. We note that the quality of IHC experiments with the TIA1 antibody varies by the supplier and lot. We provide the specific lot number for our studies.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Randomization necessarily arose based on birth order, as mice were allocated to each cohort/group as they were born and subsequently genotyped.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Experimenters were blinded to the genotype of each mouse, which was then decoded using the ear-tag identification numbers after data collection and analysis. For behavioral experiments, the behavior was quantified over the test period was scored by 2 blinded observers. For the survival study, animals were assessed daily by veterinary staff who were blinded as to the genotype of the animals. These veterinary staff made the decisions about when the mice reached the endpoint criteria. The endpoint criterion was defined as at least one of the following: dragging or paralysis of 2 or more limbs, postural instability/inability to feed, or greater than 10% loss in body weight.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Graphpad Prism was used for the statistical studies, excel was used for the experimental analysis, the DAVID bioinformatics suite was used for analysis of the mass spectrometry results.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
The P301S tau and Tia1-/-mice are available from Jackson laboratories. All the mouse strains generated by the Wolozin laboratory will be freely distributed. The Tau13, Tau 5, TOC1 and TNT1 antibodies are available from the Kanaan group (MSU). The PHF1 and CP13 antibodies are available from Peter Davies (Feinstein Institute).
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Antibodies against Tau and TIA1 have been validated in the Wolozin laboratory by performing IHC and immunoblotting on MAPT -/-or Tia1 -/-mouse tissues, as well as on rTg4510 P301L tau tissues. Commercial antibodies against other targets were validated by testing the antibodies on control tissues, and for antibodies where the epitopes are provided, by immunoadsorption. The TIA1 antibody showed lot to lot variability, so we have also provided the specific abcam lot number (abcam cat#ab40693, lot GR151575-3). 
